4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

TD Cowen initiated coverage of NewAmsterdam Pharma with a rating of Buy

Scotiabank initiated coverage of NewAmsterdam Pharma with a rating of Sector Outperform and set a new price target of $35.00

Guggenheim initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $30.00

Piper Sandler initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $37.00

RBC Capital Mkts initiated coverage of NewAmsterdam Pharma with a rating of Outperform and set a new price target of $25.00

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors. "John and Jim are seasoned veterans in the field, and each brings a differentiated skill set that will enable us to strengthen our execution across the private and public investment strategies of the firm," said Patrick Heron, Managing Partner at FLS. John has over 25 years of financial experience in the biopharmaceutical industry. Before joining FLS, John served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he led the company's successful initial public offering

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa

Round co-led by Forbion and EQT Life SciencesFinancing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pipeline programs Successful fundraising demonstrates value of Forbion platform, with multiple Forbion fund strategies supporting VectorY's development since launch AMSTERDAM, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, today announces that its Growth Opportunities Fund has co-led, together with EQT Life Sciences, a €129 million Series A financing in VectorY Therapeutics, a biotech company focusing on the development of innovative vectorized a

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s

Forbion co-leads oversubscribed Series B financing in next-generation radiopharmaceuticals companyFirst investment by its Forbion Ventures Fund VI, aimed at advancing highly impactful development-stage therapeutics companiesInvestment in Mariana Oncology leverages Forbion's track record and deep domain expertise in oncology NAARDEN, The Netherlands and MUNICH, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, today announces that it has co-led, together with Deep Track Capital, an oversubscribed $175 million Series B financing in Mariana Oncology, the first investment by its Forbion Ventures Fund VI. Founding investors Atlas Vent

NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as Forbion's first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability and impact investing, including private equity, most recently as ESG Director at Stafford Capital Partners and before that as Director, Sustainability, Private Equity at Robeco. Silva contributes her knowledge of ESG best-practice to a number of professional organizations, including as vice-chair of Invest Europe's ESG Committee, and as a member of the Responsible Investment Committee of the Du

Forbion's largest fundraising to date€750 million raised in the final close of the Forbion Ventures Fund VI €600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings the total of funds under management at Forbion to €3 billion NAARDEN, The Netherlands and MUNICH, Germany, April 19, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, today announces that it has raised €1.35 billion ($1.5 billion) for its two newest funds, bringing the total of funds under management to €3 billion. Both funds exceeded their original target sizes and represent Forbion's largest fundraising success to date. The final close of the Fo

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the completion of patient enrollment in the pivotal Phase 3 TANDEM clinical trial evaluating the fixed-dose combination ("FDC") of obicetrapib plus ezetimibe in adult patients with Heterozygous Familial Hypercholesterolemia ("HeFH") and/or Atherosclerotic Cardiovascular Disease ("ASCVD") or multiple risk factors for ASCVD, whose LDL-C is not adequately

-- New patent extends patent term for obicetrapib until July 2043 --NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 12,006,305, titled "Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof."

RBC Capital analyst Leonid Timashev reiterates NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and maintains $31 price target.

-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 --NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today

TD Cowen analyst Tyler Van Buren initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating.

First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily driven by the proceeds of the follow-on offering and warrant exercises partially offset by cash outflows related to research and development costs as the Company continues development of obicetrapib and increased spending on selling, general and administrative expenses to support the Company's growing organization.Revenue: NewAmsterdam recognized $1.4 million in revenue for the quarter ended March 31, 2024, compared to $8.6 million in the same period in 2023. This decrease was primarily due to t

Gainers GeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today. InnovAge Holding (NASDAQ:INNV) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million. Mustang Bio (NASDAQ:MBIO) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million. Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million. Seelos Therapeutics (NASDAQ:SEEL) shares increased by 4.88% to $0.29. The market

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional data from the Phase 2 ROSE2 clinical trial at the 2024 American College of Cardiology Congress ("ACC") in Atlanta, Georgia, being held April 6-8. ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National L

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and announces Price Target of $35.